RecruitingNot ApplicableNCT01035112
Magnetic Resonance Imaging of Breast Cancer
Sponsor
Stanford University
Enrollment
500 participants
Start Date
Apr 1, 1995
Study Type
INTERVENTIONAL
Conditions
Summary
To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.
Eligibility
Sex: FEMALEMin Age: 21 Years
Plain Language Summary
Simplified for easier understanding
This study uses MRI scans to get a better look at breast tissue in women who have a suspicious breast lump or abnormality detected by physical exam or mammogram.
**You may be eligible if...**
- You are a woman
- You have had a breast physical exam and a mammogram in the last 3 months
- You have a suspicious breast lump found by exam or mammogram
- You have had a previous lumpectomy for breast cancer and now have a new suspicious area on mammogram
**You may NOT be eligible if...**
- You are male
- You have a pacemaker, metal implants, or aneurysm clips in your body
- You have severe claustrophobia (fear of enclosed spaces)
- You are pregnant or currently breastfeeding
- You had an MRI with contrast dye in the last 48 hours, or iodine contrast in the last 6 hours
- You have a known allergy to MRI contrast dye
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREMRI
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01035112
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations